InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of High Risk for CAR-T Treatment Failure By Ogkologos - May 5, 2025 183 0 Facebook Twitter Google+ Pinterest WhatsApp A valuable tool for point-of-care clinical decision-making in patients with non-Hodgkin lymphoma Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Aggressive Prostate Cancer Subtype More Common Than Expected July 31, 2018 NICE doesn’t recommend olaparib for patients with certain prostate cancers September 13, 2022 Early Evaluation of Nutritional Status Is Needed to Provide Nutritional Support... September 21, 2020 Stereotactic Radiosurgery Not Superior in Terms of Pain Response Compared with... April 26, 2023 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Lutetium (177lu) Chloride Modest Population-Level Increases in Survival Observed After Implementation of Immune Checkpoint... Greater Severity of Adverse Events in Women Across Multiple Anticancer Treatment... FDA Approves Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable NSCLC
